A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, have achieved good efficacy in EGFR mutation-positive non-small-cell lung cancer (NSCLC) patients, but eventual drug resistance is inevitable. Thus, new TKI-based combination therapies should be u...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Wanjun, Ye, Fei, Yuan, Xiao, Ma, Yali, Mao, Chaoming, Li, Xiaoqin, Li, Jian, Dai, Chunhua, Qian, Fenhong, Li, Junrong, Fan, Xiujuan, Zhou, Yuepeng, Wang, Deqiang, Guo, Zhenhong, An, Huazhang, Zhang, Minghui, Chen, Deyu, Xia, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325186/
https://www.ncbi.nlm.nih.gov/pubmed/34332557
http://dx.doi.org/10.1186/s12885-021-08590-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325186/
https://www.ncbi.nlm.nih.gov/pubmed/34332557
http://dx.doi.org/10.1186/s12885-021-08590-1

Ejemplares similares